Arch Therapeutics Co-Founder Dr. Ellis-Behnke Speaks at 6th Annual CLINAM Nanomedicine Summit in Basel, Switzerland
23 Juli 2013 - 3:50PM
Marketwired
Arch Therapeutics, Inc. (OTCQB: ARTH) ("Arch"
or the "Company"), a life science company and developer of AC5™, a
novel product aimed at controlling bleeding and fluid loss in order
to provide faster and safer surgical and interventional care, is
pleased to advise that co-founding and inventing scientist, Dr.
Rutledge Ellis-Behnke, delivered a lecture titled "The Spider
Effect, how the Immune System in the Brain can be Measured and
Modulated with Nanotechnology" at the 6th annual European
Foundation for Clinical Nanomedicine (CLINAM) Summit in Basel,
Switzerland.
The focus of this year's CLINAM Summit was 'Nanomedicine &
Targeted Medicine -- the paradigm of precise, highly effective and
safe medicine with subtle influence for the benefit of patients and
mankind.' Beat Löffler, Executive Director of CLINAM, said the goal
of the 2013 Summit was "to bring together the most skilled people
in an effort to help to shape this scientific field and thereby
push the boundaries of cutting-edge Nanomedicine and Targeted
Medicine."
Ellis-Behnke, a founding board member of the International
Society of Nanomedicine, discussed the groundbreaking system he
designed to categorize the activation status of microglia using
morphological attributes. "The work represents a new measurement
system for inflammation that assigns an objective number to the
level of inflammation and thus can be used as a diagnostic to treat
and measure the response," he said.
Ellis-Behnke noted, "Inflammation is often only treated for two
weeks. However, our work indicates that inflammation can last far
longer than that before returning to a resting state, suggesting
that inflammation needs to be treated far longer than was once
thought. In order to modulate these responses, it is important to
control the leakage of blood within and between tissue components
as well as in the local environment. This can be accomplished with
novel materials."
Dr. Ellis-Behnke was instrumental in discovering the hemostatic
and other barrier properties of self-assembling peptides that could
make future surgery and interventional care faster and safer. He
proposed the development and commercialization of Arch
Therapeutics' flagship product candidate known as AC5™.
Arch Therapeutics CEO, Dr. Terrence Norchi further comments,
"Dr. Ellis-Behnke is at the forefront of emerging trends in
nanomedicine and the advice he provides our Company continues to be
of great importance. He is the lead inventor on the intellectual
property exclusively licensed by Arch Therapeutics from the
Massachusetts Institute of Technology and his work offers strategic
insights that shape our future and the roadmap for our
success."
Additional details regarding Arch Therapeutics, Inc., its
business, agreements and related matters are filed as part of the
Company's continuous public disclosure as a reporting issuer under
the Securities Exchange Act of 1934 filed with the Securities and
Exchange Commission ("SEC"), and are available at the SEC's website
at www.sec.gov. For more information, visit our website at
www.archtherapeutics.com.
About Arch Therapeutics, Inc. (OTCQB:
ARTH) Arch Therapeutics, Inc. (OTCQB: ARTH) is a medical device
company developing a novel approach to stop bleeding (hemostasis)
and control leaking (sealant) during surgery and trauma care.
Arch's goal is to develop and commercialize products based on our
innovative technology platform that make surgery and interventional
care faster and safer for patients. Arch's flagship development
stage product candidate known as AC5™ is being designed to
elegantly achieve hemostasis in minimally invasive and open
surgical procedures. Find out more at www.archtherapeutics.com.
Notice Regarding Forward-Looking
Statements This news release contains "forward-looking
statements" as that term is defined in Section 27(a) of the
Securities Act of 1933, as amended, and Section 21(e) of the
Securities Exchange Act of 1934, as amended. Statements in this
press release that are not purely historical are forward-looking
statements and include any statements regarding beliefs, plans,
expectations or intentions regarding the future. Such
forward-looking statements include, among other things, references
to novel technologies and methods, our business and product
development plans and projections, or market information. Actual
results could differ from those projected in any forward-looking
statements due to numerous factors. Such factors include, among
others, the inherent uncertainties associated with developing new
products or technologies and operating as a development stage
company, our ability to retain important members of our management
team and attract other qualified personnel, our ability to raise
the additional funding we will need to continue to pursue our
business and product development plans, our ability to develop and
commercialize products based on our technology platform, and market
conditions. These forward-looking statements are made as of the
date of this news release, and we assume no obligation to update
the forward-looking statements, or to update the reasons why actual
results could differ from those projected in the forward-looking
statements. Although we believe that any beliefs, plans,
expectations and intentions contained in this press release are
reasonable, there can be no assurance that any such beliefs, plans,
expectations or intentions will prove to be accurate. Investors
should consult all of the information set forth herein and should
also refer to the risk factors disclosure outlined in the reports
and other documents we file with the SEC, available at
www.sec.gov.
On Behalf of the Board,
Terrence W. Norchi, MD. Arch Therapeutics, Inc.
Add to Digg Bookmark with del.icio.us Add to Newsvine
Contact: ARTH Investor Relations Toll Free:
+1-855-340-ARTH (2784) (US and Canada) Email:
investors@archtherapeutics.com Website:
www.archtherapeutics.com
Arch Therapeutics (QB) (USOTC:ARTH)
Historical Stock Chart
Von Jun 2024 bis Jul 2024
Arch Therapeutics (QB) (USOTC:ARTH)
Historical Stock Chart
Von Jul 2023 bis Jul 2024